Sandoz wins Brazilian approval for its semaglutide treatment option
The generics maker says the clearance opens the way to broader patient access in one of the largest emerging obesity and diabetes markets.
DO
By Daniel Okafor · Regulatory Correspondent
Jul 29 03:00 ETSource: sandoz.com
The wire
- 01Sandoz confirmed regulatory approval in Brazil for a new semaglutide treatment option, which the company says will expand access.
- 02Approvals of non-originator semaglutide signal the start of post-exclusivity competition that pharmacists and telehealth operators will have to navigate market by market.
- 03Launch timing, presentation and pricing were not detailed in the company statement, and the approval applies only to Brazil.
From the source
Read at sandoz.comSandoz confirms regulatory approval for new semaglutide treatment option in Brazil, paving way to expand patient access